



Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsLtd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

Date: 14.02.2026

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal St, Fort, Mumbai,
Maharashtra 400001

Scrip Code: 538965**Sub: Results approved in Board Meeting held on 14.02.2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the meeting of the Board of Directors of the Company was held on 14.02.2026.

- 1) Considered and approved the Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31st December, 2025.
- 2) Took note of the Limited Review Report issued by the Statutory Auditors of the Company on the aforesaid financial results.

Further, the financial results are also available on the website of the Company at (<https://concorddrugs.in/investor-relations>) and on the website of BSE Ltd viz. www.bseindia.com.

The financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Board Meeting commenced at 03:00 PM and concluded at 04:15 PM.

This is for the information and record.

Thanking you
Yours Sincerely,

For Concord Drugs Limited

Seelam Manoj Kumar Reddy
Whole-time director
(DIN: 06991382)

STATEMENT OF UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31st December 2025

Particulars	Quarterly ended				Nine months ended			31-Mar-25 (Audited)
	31-Dec-25 (un Audited)	30-Sep-25 (un Audited)	31-Dec-24 (un Audited)	31-Dec-25 (un Audited)	31-Dec-24 (un Audited)	31-Dec-25 (un Audited)	31-Mar-25 (Audited)	
I Revenue from Operations								
a. Net sales from Operations	1,684.01	1,007.28	1,077.39	4,029.64	2,896.81	2,896.81	3,693.21	
b. Other Operating Income	2.12	0.24	0.00	2.36	0.96	0.96	1.44	
Other Income								
Total Revenue (I+II)	1,686.13	1,007.52	1,077.39	4,032.00	2,897.77	2,897.77	3,694.65	
IV Expenses								
a. Cost of Material Consumed	1,433.24	766.89	851.06	3,269.05	2,218.04	2,218.04	2,822.46	
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	0.77	-4.51	-22.76	56.90	16.43	16.43	-58.05	
c. Employees Benefit Expenses	122.19	108.00	94.51	317.30	285.82	285.82	439.13	
d. Finance Costs	29.60	39.87	42.58	111.45	118.36	118.36	171.84	
e. Depreciation and Amortisation expense	30.44	33.70	36.72	100.68	104.35	104.35	141.80	
f. Other expenses	40.61	36.67	23.21	105.22	92.70	92.70	113.34	
Total Expenses	1,656.85	980.61	1,025.32	3,960.60	2,835.70	2,835.70	3,630.52	
Profit/ (Loss) before Exceptional item and tax (III-IV)	29.28	26.91	52.07	71.40	62.07	62.07	64.13	
Exceptional Items								
Profit/ (Loss) before tax (V-VI)	29.28	26.91	52.07	71.40	62.07	62.07	64.13	
Tax Expense:								
a. Current tax	7.75	7.52	29.87	19.33	33.29	33.29	34.56	
b. Deferred tax charge/credit	7.07	7.80	14.36	20.02	19.65	19.65	18.99	
Profit/ (Loss) for the period (VII-VIII)	0.69	-0.28	15.51	-0.68	13.64	13.64	15.57	
Other Comprehensive Income								
Items that will not be reclassified to profit or loss	21.52	19.39	22.19	52.06	28.77	28.77	29.57	
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	21.52	19.39	22.19	52.06	28.77	28.77	29.57	
XI Paid up Capital								
(Face value of the share- Rs. 10 each)	1,317.50	1,000.00	1,000.00	1,317.50	1,000.00	1,000.00	1,000.00	
Other Equity								
Earnings per share (of Rs. 10 each) (in Rupees)								
a. Basic (in Rs)	3,482.21	2,441.89	2,410.56	3,482.21	2,410.56	2,410.56	2,411.36	
b. Diluted (in Rs)	0.16	0.19	0.22	0.40	0.29	0.29	0.30	
	0.16	0.19	0.22	0.40	0.29	0.29	0.30	

Notes:

1	The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under
2	The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14.02.2026
3	During the Quarter ended 31.12.2025 the company has issued 31,75,000 Equity shares at the price of Rs 36.30 per share on preferential basis in terms of Chapter V of (ICDR) regulations 2018 And allotment of 20,25,000 warrants at the price of Rs 36.30 per warrant against which 25% upfront money amounting to Rs 1,83,76,875 was received during the period.
4	The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Code viz. Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from November 21, 2025. The corresponding supporting rules under these codes are yet to be notified. The Company Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
6	The results are also available on the website of the Company www.concorddrugs.in



STATEMENT OF UN AUDITED Consolidated FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER 2025

Particulars	[Rs. in Lakhs]					
	Quarterly ended		Nine months ended			31-Mar-25 (Audited)
	31-Dec-25 (Un Audited)	30-Sep-25 (Un Audited)	31-Dec-24 (Un Audited)	31-12-2025 (Un Audited)	31-Dec-24 (Un Audited)	
I	Revenue from Operations					
	a. Net sales from Operations	1,696.63	1,027.61	1,079.94	4,084.88	3,485.29
	b. Other Operating Income	2.12	0.24	0.00	2.36	0.96
II	Other Income					
III	Total Revenue (+II)	1,698.75	1,027.85	1,079.94	4,087.24	3,486.25
IV	Expenses					
	a. Cost of Material Consumed	1,438.34	776.35	672.34	3,295.91	2,715.98
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	0.77	-4.51	142.49	56.90	16.43
	c. Employee Benefit Expenses	123.73	109.46	100.42	321.79	339.62
	d. Finance Costs	33.97	48.81	49.70	131.79	141.57
	e. Depreciation and Amortisation expense	30.67	33.94	37.04	101.39	105.31
	f. Other expenses	41.65	36.69	25.26	106.89	104.00
	Total Expenses	1,669.14	1,000.73	1,027.25	4,014.68	3,422.91
V	Profit/ (Loss) before Exceptional item and tax (III-IV)	29.61	27.13	52.69	72.56	63.34
VI	Exceptional Items					
VII	Profit/ (Loss) before tax (V-VI)					
VIII	Tax Expense:					
	a. Current tax	7.92	7.89	30.02	19.87	33.61
	b. Deferred tax charge/credit	7.15	0.06	14.51	20.32	19.97
IX	Profit/ (Loss) for the period (VII-VIII)	21.69	19.24	22.67	52.69	29.73
X	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss	-	-	-	-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	21.69	19.24	22.67	52.69	29.73
XI	Paid up Capital					
	(Face value of the share- Rs. 10 each)	1,317.50	1,000.00	1,000.00	1,317.50	1,000.00
XII	Other Equity					
	Earnings per share (of Rs. 10 each) (in Rupees)					
XIII	a. Basic (in Rs)	0.16	0.19	0.23	0.40	0.30
	b. Diluted (in Rs)	0.16	0.19	0.23	0.40	0.30

Notes:
1 The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.

2 The above Consolidated financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14.02.2026

3 During the Quarter ended 31.12.2025 the Holding company has issued 31,75,000 Equity shares at the price of Rs. 36.30 per share on preferential basis in terms of Chapter V of (ICDR) regulations, 2018 and allotment of 20,25,000 warrants at the price of Rs. 36.30 per warrant against which 25% upfront money amounting to Rs. 1,83,76,875 was received during the period.

4 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.

6 The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad
Date: 14.02.2026





PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,
Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

- Branches :
1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
 2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
 3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Consolidated Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of Concord Drugs Limited ('the group company') for the quarter ended 31st December 2025, and the year to date results for the period 1 April 2025 to 31st December 2025, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Group Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.




4. The Statement includes the results of the following entities:
Proton Remedies Private Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited financial results and other financial information, in respect of one subsidiary, whose unaudited financial results include total revenues of Rs 124.83 lakhs, total net profit after tax of Rs. 1.17 lakhs, for nine months ended 31st December, 2025, as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on unaudited interim financial results and other financial information of these entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditor.

For Pundarikashyam and Associates
Chartered Accountants
FRN: 011330S.

B. Surya Prakasa Rao
B. Surya Prakasa Rao
(Partner)
MNo: 205125
UDIN: 26205125CJYFWP4289



Place: Hyderabad
Date: 14.02.2026.



PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet,
Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

- Branches :
1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
 2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
 3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 31st December 2025, and the year to date results for the period 1 April 2025 to 31st December 2025, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India.



A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam and Associates
Chartered Accountants
FRN: 011330S.

B. Surya Prakasa Rao

B. Surya Prakasa Rao
(Partner)
MNo: 205125
UDIN: 26205125FXVLSY8861.

Place: Hyderabad
Date: 14.02.2026.

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Mode of Fund Raising	Preferential Issues
Date of Raising Funds	20-11-2025
Amount Raised	13,36,29,375/-
Report filed for Quarter ended	31-12-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	NIL
Comments of the auditors, if any	NIL

Sr .	Original Object	Modified Object, if any	Original Allocation	Modified allocation , if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object
Not Applicable as no Deviation/Variation for the quarter						

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:

There is no default on loans and debt securities for the Quarter ended 31st Dec,2025.

Sl.No	Particulars	In Rs.
1.	Loans / revolving facilities like cash credit from banks / financial institutions	0
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e. NCDs and NCRPS	0
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
3.	Total financial indebtedness of the listed entity including short- term and long-term debt	0

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter):

Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter):

Not Applicable